Aim To determine the serum levels of matrix metalloproteinase 9 (MMP-9) concentration and their association with the stage and histopathologic sizes of colorectal cancer (CRC). Methods One hundred and two patients with clinically diagnosed and histologically confirmed colorectal cancer ready for surgical treatment were included in the study. In each patient, preoperative peripheral venous blood samples were taken for determination of the concentration of MMP-9 using ELISA immunoassay test. Resected tumour specimens were studied pathologically according to the criteria of the TNM classification. All patients were divided into groups according to the TNM classification. The control group presented 30 subjects of the appropriate age and gender with no family history of cancer, clinical signs of malignancy or inflammatory bowel disease. Results The serum levels of MMP-9 were progressively increased in patients with CRC reaching the highest value in the fourth stage of CRC. It was also confirmed that the serum concentrations of MMP-9 were significantly higher in patients with pericolonic lymph nodes involvement compared to the patients with no involvement of lymph nodes, 456.4 (445.9-464.7) ng/mL vs. 438.4 (418.4-447.8) ng/mL (p<0.001). Significantly higher serum levels of MMP-9 were found in the patients with metastatic CRC, 458.5 (452.0-468.1) ng/mL compared with the CRC patients without metastasis, 445.8 (436.9-456.5) ng/mL (p<0.001). Conclusion It was confirmed that serum concentration of MMP-9 presented the significant independent risk factors for the progression of CRC.
Talmadge J, Fidler I. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010:5649–69.
2
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010:52–67.
3
Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol 2012:318–25.
4
Emara M, Cheung P-Y, Grabowski K, Sawicki G, Wozniak M. Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin Chem Lab Med 2009:993–1000.
5
Hamilton S, Aaltonen L. Pathology and Genetics of Tumours of the Digestive System 2000:104.
6
Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. AJCC cancer staging manual 2010;(7).
7
Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct 2010:985132.
8
Bendardaf R, Lamlum H, Pyrhönen S. Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004:2519–30.
9
Vihinen P, Kähäri V. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002:157–66.
10
Biasi F, Guina T, Maina M, Nano M, Falcone A, Aroasio E, et al. Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract. PLoS ONE 2012:41839.
11
Wilson S, Damery S, Stocken D, Dowswell G, Holder R, Ward S, et al. Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. Br J Cancer 2012:1431–8.
12
Damery S, Nichols L, Holder R, Ward S, Warmington S, Wilson S, et al. Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer. Br J Cancer 2013:1149–56.
13
Jonsson A, Hjalmarsson C, Falk P, Ivarsson M. Levels of matrix metalloproteinases differ in plasma and serum -aspects regarding analysis of biological markers in cancer. Br J Cancer 2016:703–6.
14
Herszényi L, Hritz I, Lakatos G, Varga M, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci 2012:13240–63.
15
Ting W, Chen L, Pao J, Yang Y, You B, Chang T, et al. Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci 2013:1022–7.
16
Asano T, Tada M, Cheng S, Takemato N, Kuramae T, Abe M, et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res 2008:32–42.
17
Van Der Jagt M, Wobbes T, Strobbe L, Sweep F, Span P. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol 2010:259–69.
18
Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004:101–17.
19
Said A, Raufman J-P, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers 2014:366–75.
20
Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009:613–8.
21
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, Vecchia L, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015:779–86.
22
Fearonn E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990:759–67.
23
Valko M, Rhodes C, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interac 2006:1–40.
24
Gopčević K, Rovčanin B, Tatić S, Krivokapić Z, Gajić M, Dragutinović V. Activity of superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase in different stages of colorectal carcinoma. Dig Dis Sci 2013:2646–52.
25
Herszényi L, Barabás L, Hritz I, István G, Tulassay Z. Impact of proteolytic enzymes in colorectal cancer development and progression. World J Gastroenterol 2014:13246–57.
26
Iyer R, Patterson N, Fields G, Lindsey M. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012:919–30.
27
Roy R, Yang J, Moses M. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clinl Oncol 2009:5287–97.
28
Hong S, Kang Y, Lee B, Lee W, Jang Y, Paik I, et al. Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol 2011:133–9.
29
El-Badrawy M, Yousef A, Shaalan D, Elsamanoudy A. Matrix metalloproteinase-9 expression in lung cancer patients and its relation to serum MMP-9 activity, pathologic type, and prognosis. J Bronchology Interv Pulmonol 2014:327–34.
30
Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin 2016:7–30.
31
Zhang W, Hu X, -X, Yang X-Z, Wang Q, Cheng H, et al. Combined detection of serum matrix metalloproteinase 9, acetyl heparinase and cathepsin L in diagnosis of ovarian cancer. Chin J Cancer Res 2012:67–71.
32
Zhang L, Shi J, Feng J, Klocker H, Lee C, Zhang J. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 2004:327–32.
33
FUNDING No specific funding was received for this study. TRANSPARENCY DECLARATIONS Competing interests: none to declare n.d.
34
Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/ NGAL in breast cancer disease. BMC Cancer 2009:390.
35
Hormigo A, Gu B, Karimi S, Riedel E, Panageas K, Edgar M, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2017:1422–31.
36
Herszényi L, Hritz I, Lakatos G, Varga M, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci 2012:13240–63.
37
Yang B, Su K, Gao J, Rao Z. Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev 2012:1049–52.
38
Hurst N, Stocken D, Wilson S, Keh C, Wakelam M, Ismail T. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 2007:971–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
